Physician profile
Jane Strader
NPI 1629272901
$5,873.94
in general payments reported to CMS, 2019-2025
30 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,061 · 2020: $617 · 2021: $1,111 · 2022: $567 · 2023: $684 · 2024: $826 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,518.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $819.35 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $651.11 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Abbvie INC. | $641.95 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $500.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $480.33 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $405.94 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $396.13 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $377.47 | 2019-2025 | Breztri, Bevespi Aerosphere |
| Otsuka America Pharmaceutical, INC. | $208.79 | 2022-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $152.10 | 2021 | |
| Abbott Laboratories | $139.79 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $119.31 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $110.07 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.98 | 2021-2023 | |
| Phadia US INC. | $88.44 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.80 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $82.43 | 2019 | |
| Axsome Therapeutics, INC. | $80.43 | 2023-2025 | Auvelity, Sunosi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.95 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $72.98 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $49.21 | 2021 | |
| Supernus Pharmaceuticals, INC. | $43.49 | 2021-2022 | |
| Corcept Therapeutics | $39.23 | 2023-2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $32.62 | 2022 | |
| Novartis Pharmaceuticals Corporation | $31.74 | 2020-2022 | |
| Amarin Pharma, INC. | $25.78 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.98 | 2022 | |
| Verona Pharma, INC. | $18.64 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $14.87 | 2022 | |
| Allergan, INC. | $14.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Strader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.